Filtered By:
Specialty: Cancer & Oncology
Condition: Thrombocytopenia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
CONCLUSIONS: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.PMID:37477938 | DOI:10.1158/1078-0432.CCR-23-0388
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Qingsheng Xu Kaiyuan Huang Xiangqi Meng Yuxiang Weng Luyuan Zhang Linghao Bu Xiujue Zheng Jinquan Cai Renya Zhan Qun Chen Source Type: research

Cancers, Vol. 14, Pages 118: Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
In conclusion, PHP is a safe and effective salvage treatment for liver-dominant metastatic uveal melanoma. Serious AEs—though rare—demand careful patient selection.
Source: Cancers - December 27, 2021 Category: Cancer & Oncology Authors: Cornelia L. A. Dewald Mia-Maria Warnke Roland Br üning Martin A. Schneider Peter Wohlmuth Jan B. Hinrichs Anna Saborowski Arndt Vogel Frank K. Wacker Tags: Article Source Type: research

Management of Primary Central Nervous System Lymphoma Using  Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort
ConclusionCIAC using HD-MTX-based protocols with OBBBD is a safe and well-tolerated procedure for the management of PCNSL. Our data suggests better PFS and survival outcomes compared to IV protocols with less hematologic toxicity and good tolerability, especially in the elderly.
Source: Frontiers in Oncology - January 20, 2021 Category: Cancer & Oncology Source Type: research

Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
AbstractPurpose of ReviewThe anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients.Recent FindingsThere are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer...
Source: Current Oncology Reports - April 3, 2019 Category: Cancer & Oncology Source Type: research

Platelet count is associated with outcome in cancer patients with stroke
ConclusionIn cancer patients with CVD, thrombocytopenia at the time of CVD diagnosis and altered mental status during initial clinical evaluation were associated with higher mortality, which should be confirmed in future studies.
Source: Journal of Neuro-Oncology - November 28, 2018 Category: Cancer & Oncology Source Type: research

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992. PMID: 29921512 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM Tags: Gynecol Oncol Source Type: research

Idiopathic Thrombocytopenia Purpura Masking Hodgkin Disease: A Paraneoplastic Syndrome or Simply a Mere Association?
We report a 74-year-old female who presented to the emergency department complaining of bruising and stroke-like symptoms. She underwent a negative stroke work-up but was found to have profoundly low platelets and splenomegaly on examination. An abdominal CT scan was ordered, showing pelvic lymphadenopathy. Lymphoma was suspected. However, subsequent bone marrow and lymph node biopsies showed no evidence of this. She was treated for immune thrombocytopenia purpura (ITP) to no avail while a lymphoma work-up continued. Months later, a third and final lymph node biopsy yielded evidence of Hodgkin disease (HD) and she began tr...
Source: Case Reports in Oncology - December 19, 2017 Category: Cancer & Oncology Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications
ConclusionsHepatectomy patients meeting BL criteria have an overall post‐hepatectomy mortality rate that is triple that of non‐BL patients. With less clinical reserve, BL patients who suffer SC are at greater risk of post‐hepatectomy death. J. Surg. Oncol. © 2016 Wiley Periodicals, Inc.
Source: Journal of Surgical Oncology - November 2, 2016 Category: Cancer & Oncology Authors: Bradford J. Kim, Ching ‐Wei D. Tzeng, Amanda B. Cooper, Jean‐Nicolas Vauthey, Thomas A. Aloia Tags: Research Article Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
Conclusion The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
Source: Neuro-Oncology - June 6, 2016 Category: Cancer & Oncology Authors: Saran, F., Chinot, O. L., Henriksson, R., Mason, W., Wick, W., Cloughesy, T., Dhar, S., Pozzi, E., Garcia, J., Nishikawa, R. Tags: Clinical Investigations Source Type: research